Literature DB >> 12032857

N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth.

Elissavet Hatzi1, Carol Murphy, Andreas Zoephel, Heidi Rasmussen, Lucia Morbidelli, Horst Ahorn, Keita Kunisada, Ulrike Tontsch, Michael Klenk, Keiko Yamauchi-Takihara, Marina Ziche, Einar K Rofstad, Lothar Schweigerer, Theodore Fotsis.   

Abstract

Angiogenesis is an indispensable prerequisite for the progression and metastasis of solid malignancies. Tumor angiogenesis appears to be governed by alterations of tumor suppressor or oncogenes operant in a broad range of tumors. We have addressed this issue in neuroblastoma, a malignancy characterized by the near-exclusive amplification and overexpression of the N-Myc oncogene. Here, we report that N-Myc overexpression results in down-regulation of interleukin-6 (IL-6) and that IL-6 is an inhibitor of endothelial cell proliferation and VEGF-induced rabbit corneal angiogenesis. STAT3 is instrumental for IL-6 activity as infection with adenoviruses expressing a phosphorylation deficient STAT3 mutant renders endothelial cells insensitive to the antiproliferative action of IL-6. Finally, though IL-6 does not influence neuroblastoma cell growth, IL-6-expressing xenograft tumors in mice exhibit reduced neovascularization and suppressed growth. Our data shed new light on the mechanisms by which N-myc oncogene amplification enhances the malignant phenotype in neuroblastomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032857     DOI: 10.1038/sj.onc.1205440

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Absence of PAF actions increases angiogenesis.

Authors:  Marina Ziche
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

2.  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Authors:  Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine.

Authors:  Monique B Nilsson; Robert R Langley; Isaiah J Fidler
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

4.  VEGFR2 survival and mitotic signaling depends on joint activation of associated C3ar1/C5ar1 and IL-6R-gp130.

Authors:  Ming-Shih Hwang; Michael G Strainic; Elliot Pohlmann; Haesuk Kim; Elzbieta Pluskota; Diana L Ramirez-Bergeron; Edward F Plow; M Edward Medof
Journal:  J Cell Sci       Date:  2019-03-28       Impact factor: 5.285

Review 5.  Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies.

Authors:  Mans Broekgaarden; Ruud Weijer; Thomas M van Gulik; Michael R Hamblin; Michal Heger
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

6.  Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma.

Authors:  Rachel A Egler; Susan M Burlingame; Jed G Nuchtern; Heidi V Russell
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

7.  Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells.

Authors:  Tasnim Ara; Liping Song; Hiroyuki Shimada; Nino Keshelava; Heidi V Russell; Leonid S Metelitsa; Susan G Groshen; Robert C Seeger; Yves A DeClerck
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

Review 8.  Neuroblastoma and MYCN.

Authors:  Miller Huang; William A Weiss
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

9.  Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells.

Authors:  Martin Michaelis; Denise Klassert; Susanne Barth; Tatyana Suhan; Rainer Breitling; Bernd Mayer; Nora Hinsch; Hans W Doerr; Jaroslav Cinatl; Jindrich Cinatl
Journal:  Mol Cancer       Date:  2009-09-29       Impact factor: 27.401

10.  MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin.

Authors:  Samuele Gherardi; Emanuele Valli; Daniela Erriquez; Giovanni Perini
Journal:  Front Oncol       Date:  2013-03-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.